Evolution of Partial Resistance to Artemisinins in Malaria Parasites in Uganda
University of California, San Francisco · Norwegian Womens Public Health Association · +5 more institutions
Abstract
to the artemisinin component of artemisinin-based combination therapies, the most important malaria drugs, emerged in Southeast Asia and now threatens East Africa. Partial resistance, which manifests as delayed clearance after therapy, is mediated principally by mutations in the kelch protein K13 (PfK13). Limited longitudinal data are available on the emergence and spread of artemisinin resistance in Africa.
) and analyzed relatedness using molecular methods. We assessed malaria metrics longitudinally in eight Ugandan districts from 2014 through 2021.
Citation impact
- FWCI
- 57.35
- Percentile
- 100%
- References
- 41
Authors
17- MDMelissa D. ConradCorresponding
University of California, San Francisco, Norwegian Womens Public Health Association
- VAVictor Asua
Infectious Diseases Research Collaboration, Norwegian Womens Public Health Association, University of Tübingen
- SGShreeya Garg
University of California, San Francisco, Norwegian Womens Public Health Association
- DGDavid Giesbrecht
Brown University, Norwegian Womens Public Health Association
- KNKaramoko Niaré
Brown University, Norwegian Womens Public Health Association
Topics & keywords
- Resistance (ecology)
- Malaria
- Biology
- Ecology
- Immunology
- Good health and well-being